Keros Therapeutics KROS Stock
Keros Therapeutics Price Chart
Keros Therapeutics KROS Financial and Trading Overview
| Keros Therapeutics stock price | 14.21 USD |
| Previous Close | 38.59 USD |
| Open | 38.32 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 900 |
| Day's Range | 37.44 - 39.26 USD |
| 52 Week Range | 24.38 - 59.96 USD |
| Volume | 609.93K USD |
| Avg. Volume | 202.69K USD |
| Market Cap | 1.15B USD |
| Beta (5Y Monthly) | 1.224178 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 95 USD |
KROS Valuation Measures
| Enterprise Value | 804.22M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.1510134 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 3.2320628 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.244 |
Trading Information
Keros Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.224178 |
| 52-Week Change | 41.30% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 59.96 USD |
| 52 Week Low | 24.38 USD |
| 50-Day Moving Average | 44.63 USD |
| 200-Day Moving Average | 46.21 USD |
KROS Share Statistics
| Avg. Volume (3 month) | 202.69K USD |
| Avg. Daily Volume (10-Days) | 353.75K USD |
| Shares Outstanding | 29.58M |
| Float | 22.72M |
| Short Ratio | 4.27 |
| % Held by Insiders | 7.78% |
| % Held by Institutions | 86.49% |
| Shares Short | 821.9K |
| Short % of Float | 4.41% |
| Short % of Shares Outstanding | 2.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.13% |
| Return on Equity (ttm) | -40.20% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -87265000 USD |
| EBITDA | -128805000 USD |
| Net Income Avi to Common (ttm) | -116297000 USD |
| Diluted EPS (ttm) | -4.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 351.43M USD |
| Total Cash Per Share (mrq) | 11.88 USD |
| Total Debt (mrq) | 13.99M USD |
| Total Debt/Equity (mrq) | 3.94 USD |
| Current Ratio (mrq) | 23.433 |
| Book Value Per Share (mrq) | 12.014 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -102870000 USD |
| Levered Free Cash Flow (ttm) | -65870124 USD |
Profile of Keros Therapeutics
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 1050 Waltham Street |
| ZIP | 02421 |
| Phone | 617 314 6297 |
| Website | https://www.kerostx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 107 |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Q&A For Keros Therapeutics Stock
What is a current KROS stock price?
Keros Therapeutics KROS stock price today per share is 14.21 USD.
How to purchase Keros Therapeutics stock?
You can buy KROS shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Keros Therapeutics?
The stock symbol or ticker of Keros Therapeutics is KROS.
Which industry does the Keros Therapeutics company belong to?
The Keros Therapeutics industry is Biotechnology.
How many shares does Keros Therapeutics have in circulation?
The max supply of Keros Therapeutics shares is 41.21M.
What is Keros Therapeutics Price to Earnings Ratio (PE Ratio)?
Keros Therapeutics PE Ratio is now.
What was Keros Therapeutics earnings per share over the trailing 12 months (TTM)?
Keros Therapeutics EPS is -5 USD over the trailing 12 months.
Which sector does the Keros Therapeutics company belong to?
The Keros Therapeutics sector is Healthcare.
Keros Therapeutics KROS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2065.14 USD — |
-0.04
|
— — | 2039.56 USD — | 2065.23 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}